The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study

Jakob Michael Riedl, Florian Posch, Gerald Prager, Wolfgang Eisterer, Leopold Oehler, Thamer Sliwa, Klaus Wilthoner, Andreas Petzer, Petra Pichler, Eva Hubmann, Thomas Winder, Sonja Burgstaller, Markus Korger, Johannes Andel, Richard Greil, Hans-Joerg Neumann, Martin Pecherstorfer, Kathrin Philipp-Abbrederis, Angela Djanani, Birgit GruenbergerFriedrich Laengle, Ewald Wöll, Armin Gerger

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

37 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science